Figure 4.
Ruxolitinib (Ruxo) reduces the expansion of T cells and neutrophils in primary HLH. (A) Summarized data of the frequency and absolute numbers of splenic CD8+ T cells (left panels), CD4+ T cells gated on TCRb+CD19− live cells (middle panels), and LCMV-specific (Db gp33) CD8+ T cells gated on CD8+ T cells (right panels). (B) Frequency of splenic monocytes (Ly6ChiLy6G−) and neutrophils (Ly6CintLy6G+) of CD11b+CD11c− cells. Data (mean ± standard deviation) are representative of 2 independent experiments. n = 5 mice per group. (C) Representative hematoxylin and eosin–stained liver sections (top row) and immunohistochemical staining of CD3+ (middle row) and Neut7-4+ (lower row) cells from naive Prf1−/− mice or mice infected with LCMV that were left untreated (UnRx) or treated with αIFN-γ or Ruxo. Original magnification ×200. (D) Data were quantitated and plotted as percentage area of inflammation (upper left panel), number of inflammatory foci per field of view at 2× magnification (upper right panel) and the percentages of Neut7-4+ cells (lower left panel) and CD3+ cells (lower right panel). Data were collected from 2 independent experiments (n = 4 mice per group). Samples were randomly chosen for histological analysis. *P < .05, **P < .01, ***P < .001, ****P < .0001.